Polysaccharide-Based Theranostic Systems for Combined Imaging and Cancer Therapy
Recent Advances and Challenges
Gupta, Aastha; Sood, Ankur; Fuhrer, Erwin; Djanashvili, Kristina; Agrawal, Garima

DOI
10.1021/acsbiomaterials.1c01631

Publication date
2022

Document Version
Final published version

Published in
ACS Biomaterials Science and Engineering

Citation (APA)

Important note
To cite this publication, please use the final published version (if applicable).
Please check the document version above.

Copyright
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Takedown policy
Please contact us and provide details if you believe this document breaches copyrights.
We will remove access to the work immediately and investigate your claim.
Green Open Access added to TU Delft Institutional Repository

'You share, we take care!' - Taverne project

https://www.openaccess.nl/en/you-share-we-take-care

Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.
Polysaccharide-Based Theranostic Systems for Combined Imaging and Cancer Therapy: Recent Advances and Challenges

Aastha Gupta, Ankur Sood, Erwin Fuhrer, Kristina Djanashvili, and Garima Agrawal*

ABSTRACT: Designing novel systems for efficient cancer treatment and improving the quality of life for patients is a prime requirement in the healthcare sector. In this regard, theranostics have recently emerged as a unique platform, which combines the benefits of both diagnosis and therapeutics delivery. Theranostics have the desired contrast agent and the drugs combined in a single carrier, thus providing the opportunity for real-time imaging to monitor the therapy results. This helps in reducing the hazards related to treatment overdose or underdose and gives the possibility of personalized therapy. Polysaccharides, as natural biomolecules, have been widely explored to develop theranostics, as they act as a matrix for simultaneously loading both contrast agents and drugs for their utility in drug delivery and imaging. Additionally, their remarkable physicochemical attributes (biodegradability, satisfactory safety profile, abundance, and diversity in functionality and charge) can be tuned via postmodification, which offers numerous possibilities to develop theranostics with desired characteristics. Hence, we provide an overview of recent advances in polysaccharide matrix-based theranostics for drug delivery combined with magnetic resonance imaging, computed tomography, positron emission tomography, single photon emission computed tomography, and ultrasound imaging. Herein, we also summarize the toxicity assessment of polysaccharides, associated contrast agents, and nanotoxicity along with the challenges and future research directions.

KEYWORDS: Polysaccharides, Theranostics, Drug delivery, Imaging, Contrast agent, Toxicity

1. INTRODUCTION

Cancer is one of the most devastating diseases, and the number of cancer patients is increasing globally every year. The effective way of addressing this disease requires an early diagnosis-based treatment. To achieve this, scientists have made enormous efforts in recent years to develop various strategy-based nanomedicines by utilizing the concepts of modern nanotechnology. In this regard, significant attention has been given to developing theranostics, which are basically nanosystems that can achieve imaging combined with therapeutics delivery (Figure 1). After the inception of this term “theranostics” in the 2000s by Funkhouser, this area has seen tremendous development in the last two decades.

In this context, a variety of synthetic polymers such as polyethylene glycol (PEG), polyvinylcaprolactam (PVCL), polycaprolactone (PCL), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and poly(acrylic acid) (PAA) have been explored for designing nanocarriers for cancer therapy. The use of synthetic polymers gives us the possibility of controlling the molecular weight, mechanical properties, chemical functionality, and reproducibility. On the other hand, natural polymers such as polysaccharides have gained rapidly growing interest, as they provide the advantages of inherent biocompatibility, biodegradability, and nonimmunogenicity, which are crucial for developing efficient theranostic systems. To achieve the targeted physicochemical properties with high efficiency, these polysaccharides can be further modified by chemical functionalization. Additionally, various natural and synthetic polymers have also been combined via grafting techniques resulting in a hybrid polymer matrix for designing theranostic systems.

Further, to obtain a theranostic system capable of drug delivery and imaging, various imaging agents including metal nanoparticles, small molecule complex, radioactive agents, and micro/nanobubbles have been explored in combination with natural polymer-based nanocarriers. Based on the properties of the imaging agent used, the developed theranostic system can be utilized for different imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single photon emission computed tomography (SPECT), and ultrasound imaging.

Received: December 28, 2021
Accepted: April 20, 2022
Published: May 5, 2022
A number of articles have been reported in the literature that discuss the fundamentals of theranostics and various polymeric systems mainly based on synthetic polymers. However, very little attention has been paid to polysaccharide-based matrixes for designing theranostic systems. The review articles from Jaymand et al. and Świerczewska et al. describe the structure and physicochemical properties of different polysaccharides and how they can be modified for developing theranostic systems. However, a comprehensive overview of their use as a biopolymer matrix for theranostic systems is missing. To the best of our knowledge based on the careful observation of literature articles, this is a timely comprehensive review describing the recent advancement in the use of polysaccharide-based matrixes with nanomaterials for single/multimodal imaging techniques (e.g., MRI, CT, PET/SPECT, and ultrasound imaging) combined with drug delivery. Apart from providing the readers with a brief overview of various contrast agents used in these imaging methods, we also discuss the toxicity issue related to the contrast agents and different challenges that need to be overcome to ensure the successful commercial application of currently lab-scale theranostic systems.

2. TECHNICAL SPECIFICATIONS OF IMAGING SYSTEMS WITH CONTRAST AGENTS

2.1. MRI and Contrast Agents. 2.1.1. Contrast Concepts in MRI. The signal obtained in standard clinical MRI is based on the availability of abundant protons in the tissue. Spatial encoding is obtained by controlled superposition of short-time weak magnetic fields produced by coils featuring a linear spatial gradient. The typical MRI sound arises from switching these coils to produce these intermittent weak magnetic fields. This yields a position-dependent frequency shift of spatially distributed spins which can be used to extract the spatial origin of the signal (data is collected in the so-called k-space). There are two major contrast mechanisms which are used extensively in MRI: (i) T1-weighting and (ii) T2-weighting. T1-weighting uses the fact that the longitudinal relaxation (T1-relaxation) varies significantly among different tissue types. Hence, with a certain timing protocol of excitation and acquisition, a so-called MR sequence, the degree of saturation differs among tissue types. This approach results in signal strength variation among different tissues yielding the desired contrast. T2-weighting uses the fact that the transverse relaxation time (T2-relaxation) differs among tissue types. Hence, specific MR sequences have been developed in which the signal strength varies among tissues exhibiting shorter and longer transverse relaxation times. For both MR image types, there is an intrinsic contrast due to different proton contents. MR sequences with no T1- and T2-weighting yield pure contrast due to proton density, so-called proton-density weighted images. In the last 30 years, there have been major breakthroughs in developing further MR sequences which facilitate the application of more advanced contrast mechanisms. Few examples are the visualization of flow (flow MRI), contrast due to diffusion mechanisms (diffusion weighted imaging (DWI) and diffusion tensor imaging (DTI)), MR thermometry to measure temperature, and, probably most famous, functional MRI (fMRI) which builds up contrast due to blood-oxygen-level-dependence (BOLD) and enables the visualization of active brain areas.

In summary, MRI contains manifold intrinsic contrast mechanisms; yet there are two main types of contrast agents with applications in medical diagnostics. The contrast agents can be classified by their ability to change the relaxation rates \( R_1 = 1/T_1 \) and \( R_2 = 1/T_2 \) which leads to the definition of \( r_1 \) for the longitudinal relaxivity and \( r_2 \) for the transverse relaxivity. The effect of a contrast agent to change the immanent relaxation of a target tissue is given by eq 1:

\[
\frac{1}{T_1} = \frac{1}{T_{1i}} + r_1 \times [CA]
\]

(1)

\((1/T_1)\) describes the immanent relaxation of a tissue, whereas \((1/T_{1i})\) describes the relaxation rate when a contrast agent is present. The relaxivity \( r_1 \) of a contrast agent is expressed in units of mM\(^{-1}\) s\(^{-1}\) and \([CA]\) describes the concentration of the contrast agent. A brief introduction to \( T_{1i} \) and \( T_{2i} \)-contrast agents is given in the next section.

2.1.2. Contrast Agents in MRI. 2.1.1. Contrast Concepts in MRI. The signal obtained in standard clinical MRI is based on the availability of abundant protons in the tissue. Spatial encoding is obtained by controlled superposition of short-time weak magnetic fields produced by coils featuring a linear spatial gradient. The typical MRI sound arises from switching these coils to produce these intermittent weak magnetic fields. This yields a position-dependent frequency shift of spatially distributed spins which can be used to extract the spatial origin of the signal (data is collected in the so-called k-space). There are two major contrast mechanisms which are used extensively in MRI: (i) T1-weighting and (ii) T2-weighting. T1-weighting uses the fact that the longitudinal relaxation (T1-relaxation) varies significantly among different tissue types. Hence, with a certain timing protocol of excitation and acquisition, a so-called MR sequence, the degree of saturation differs among tissue types. This approach results in signal strength variation among different tissues yielding the desired contrast. T2-weighting uses the fact that the transverse relaxation time (T2-relaxation) differs among tissue types. Hence, specific MR sequences have been developed in which the signal strength varies among tissues exhibiting shorter and longer transverse relaxation times. For both MR image types, there is an intrinsic contrast due to different proton contents. MR sequences with no T1- and T2-weighting yield pure contrast due to proton density, so-called proton-density weighted images. In the last 30 years, there have been major breakthroughs in developing further MR sequences which facilitate the application of more advanced contrast mechanisms. Few examples are the visualization of flow (flow MRI), contrast due to diffusion mechanisms (diffusion weighted imaging (DWI) and diffusion tensor imaging (DTI)), MR thermometry to measure temperature, and, probably most famous, functional MRI (fMRI) which builds up contrast due to blood-oxygen-level-dependence (BOLD) and enables the visualization of active brain areas. In summary, MRI contains manifold intrinsic contrast mechanisms; yet there are two main types of contrast agents with applications in medical diagnostics. The contrast agents can be classified by their ability to change the relaxation rates \( R_1 = 1/T_1 \) and \( R_2 = 1/T_2 \) which leads to the definition of \( r_1 \) for the longitudinal relaxivity and \( r_2 \) for the transverse relaxivity. The effect of a contrast agent to change the immanent relaxation of a target tissue is given by eq 1:

\[
\frac{1}{T_1} = \frac{1}{T_{1i}} + r_1 \times [CA]
\]

(1)

\((1/T_1)\) describes the immanent relaxation of a tissue, whereas \((1/T_{1i})\) describes the relaxation rate when a contrast agent is present. The relaxivity \( r_1 \) of a contrast agent is expressed in units of mM\(^{-1}\) s\(^{-1}\) and \([CA]\) describes the concentration of the contrast agent. A brief introduction to \( T_{1i} \) and \( T_{2i} \)-contrast agents is given in the next section.

2.1.2. Contrast Agents in MRI. 2.1.1. Contrast Concepts in MRI. The signal obtained in standard clinical MRI is based on the availability of abundant protons in the tissue. Spatial encoding is obtained by controlled superposition of short-time weak magnetic fields produced by coils featuring a linear spatial gradient. The typical MRI sound arises from switching these coils to produce these intermittent weak magnetic fields. This yields a position-dependent frequency shift of spatially distributed spins which can be used to extract the spatial origin of the signal (data is collected in the so-called k-space). There are two major contrast mechanisms which are used extensively in MRI: (i) T1-weighting and (ii) T2-weighting. T1-weighting uses the fact that the longitudinal relaxation (T1-relaxation) varies significantly among different tissue types. Hence, with a certain timing protocol of excitation and acquisition, a so-called MR sequence, the degree of saturation differs among tissue types. This approach results in signal strength variation among different tissues yielding the desired contrast. T2-weighting uses the fact that the transverse relaxation time (T2-relaxation) differs among tissue types. Hence, specific MR sequences have been developed in which the signal strength varies among tissues exhibiting shorter and longer transverse relaxation times. For both MR image types, there is an intrinsic contrast due to different proton contents. MR sequences with no T1- and T2-weighting yield pure contrast due to proton density, so-called proton-density weighted images. In the last 30 years, there have been major breakthroughs in developing further MR sequences which facilitate the application of more advanced contrast mechanisms. Few examples are the visualization of flow (flow MRI), contrast due to diffusion mechanisms (diffusion weighted imaging (DWI) and diffusion tensor imaging (DTI)), MR thermometry to measure temperature, and, probably most famous, functional MRI (fMRI) which builds up contrast due to blood-oxygen-level-dependence (BOLD) and enables the visualization of active brain areas. In summary, MRI contains manifold intrinsic contrast mechanisms; yet there are two main types of contrast agents with applications in medical diagnostics. The contrast agents can be classified by their ability to change the relaxation rates \( R_1 = 1/T_1 \) and \( R_2 = 1/T_2 \) which leads to the definition of \( r_1 \) for the longitudinal relaxivity and \( r_2 \) for the transverse relaxivity. The effect of a contrast agent to change the immanent relaxation of a target tissue is given by eq 1:

\[
\frac{1}{T_1} = \frac{1}{T_{1i}} + r_1 \times [CA]
\]

(1)

\((1/T_1)\) describes the immanent relaxation of a tissue, whereas \((1/T_{1i})\) describes the relaxation rate when a contrast agent is present. The relaxivity \( r_1 \) of a contrast agent is expressed in units of mM\(^{-1}\) s\(^{-1}\) and \([CA]\) describes the concentration of the contrast agent. A brief introduction to \( T_{1i} \) and \( T_{2i} \)-contrast agents is given in the next section.
decay of the MR signal. The shorter the decoherence time of a certain tissue type, the less signal is acquired after a certain waiting time (echo time = TE). As a rule of thumb, we can state that $T_2$-relaxation time increases with molecular tumbling, which means that unbound small molecules have long relaxation times. This explains the $T_2$-relaxation of water in the range of seconds. The main source of decoherence is dipole–dipole interactions. Due to the relatively larger gyromagnetic ratio of electrons compared to protons, electron–proton interactions are more powerful in inducing $T_2$ relaxation than proton–proton interactions. Therefore, molecules with unpaired electrons, which are paramagnetic materials, are the main source for $T_2$ contrast agents.

The most common $T_2$-contrast agents are superparamagnetic iron-oxide nanoparticles (SPIONPs). In applications for clinical MRI, these particles are embedded in ligands. $T_2$-contrast agents exhibit a negative contrast effect. This means that the regions where contrast agents accumulate appear dark because the rapid $T_2$ relaxation inhibits the emission of signals from these regions. Current research in the field of developing $T_2$ contrast agent development investigates the application of metal-alloy particles and magnetosomes. Because of their biological origin, magnetosomes are of particular interest in developing contrast agents, as they promise a high degree of biocompatibility.

Hyperpolarization. Another option in MRI to increase signal in general is to use the effect of hyperpolarization. The net magnetization is drastically enhanced due to non-equilibrium spin polarization. This approach makes it possible to obtain signals from polarizable substances such as Xenon gases. Xenon-enhanced imaging has important applications in lung function analysis.

2.2. CT and Contrast Agents. 2.2.1. Contrast Concepts in CT. Computed tomography (CT) is the most commonly applied noninvasive imaging method in the daily clinical routine for the diagnosis of various diseases, since it is faster and less expensive compared to other imaging methods such as MRI. The imaging modality of CT makes use of tissue-dependent absorption of X-rays. Spatial encoding is obtained by measuring the absorption of X-rays with different optical paths through the desired object. While a set of parallel-rays or fan-out-rays are simultaneously transmitted through a slice, different angles are obtained by rotating the emitter and detector element around the patient. The raw data enables 2D- and 3D-image reconstructions based on Radon- and Fourier-transformation. In a simple model, we can express the attenuation coefficient $\mu$ of the X-rays using eq 2.

$$\mu = \frac{\rho Z^4}{AE^2}$$

In this equation, $\rho$ denotes the mass density of a material, $Z$ the atomic number, $A$ the atomic mass, and $E$ the energy of the X-rays. From here, we can derive some important rules of thumb for the inherent contrast mechanism in CT. Tissue with larger $\rho$, for example, bone tissue, has approximately twice the density than soft tissue and hence absorbs more X-ray energy due to the higher attenuation coefficient. In the realm of CT methodology, the absorption of different tissues is measured in Hounsfield units (HU). The HU coefficient is determined according to eq 3.

$$\text{HU} = \frac{\mu_{\text{Tissue}} - \mu_{\text{Water}}}{\mu_{\text{Water}}} \times 1000$$

Contrast between soft tissue and hard tissue (e.g., bones and teeth with $\text{HU} \approx 1000$) is generally large enough to provide sufficient contrast-to-noise ratio (CNR) for image analysis. On the other hand, the soft tissue contrast, which is by inherent contrast mechanisms, is most often not satisfactory. For example, many soft tissues have contrast values between 30 and 100 HU, which results in weak contrast between two soft-tissue types. An exceptional case is the lung because the large amount of air within lung tissue yields weaker attenuation compared to the surrounding tissue. Thus, CT, next to conventional X-ray imaging, is the method of choice for lung cancer diagnostics, because there is large contrast between a solid tumor and the surrounding lung tissue.

2.2.2. Contrast Agents in CT. Because inherent soft tissue contrast in CT is weak, contrast agents play an important role in CT imaging. Increased contrast in CT is reached by artificially increasing the absorption of X-rays at the target location. Looking at the simple model of eq 1, we can see that the X-ray absorption is proportional to the fourth power of the atomic number. From this, it is comprehensible that we can achieve large attenuations by establishing an excess of elements with high atomic number at a certain location. Further important properties for a CT contrast agent are sufficiently long tissue retention time, large affinity for the target tissue, solubility, and nontoxicity, and the substance or its metabolites must not accumulate in the body. The largest group of chemical agents for CT contrast agents are based on iodine $(Z = 53)$. A second group of contrast agents are lanthanide-based contrast agents. Here, Gd-based $(Z = 64)$ and Dy-based $(Z = 66)$ contrast agents are of particular interest and are commercially available. These contrast agents are also used to increase $T_1$-relaxation in MRI (see section 2.1.2) which explains the capability of these elements for use as contrast agents in dual-mode imaging modalities for combined CT/MR-imaging. A third group of CT contrast agents is gold nanoparticles $(Z = 79, \text{Au NPs})$ with an increased contrast-per-unit weight compared to iodine and gadolinium. Au NPs are a promising material due to the high attenuation ratio in combination with the biocompatibility. However, as gold is considered a nontoxic material, the toxicological aspect of Au NPs is still being debated. Another potential limitation of Au NPs is the high price which may render Au NPs too expensive for daily clinical use. Alternatives are other metallic contrast agents based on bismuth $(Z = 83)$, tantalum $(Z = 73)$, and platinum $(Z = 78)$, to name a few. One important gas type to enhance CT contrast is Xenon $(Z = 54)$, a gas with good solubility in blood and adipose tissue and the ability to cross the blood-brain barrier. It furthermore finds application in analysis of the lung ventilation system. Due to its application in CT and MRI, Xe may be a candidate for dual use in CT/MRI. A detailed analysis of different CT contrast agents is provided by Lusic et al.

2.3. PET/SPECT Contrast Agents. 2.3.1. Contrast Concepts in PET/SPECT. In contrast to MRI and CT, the image modalities of PET and SPECT do not have intrinsic contrast mechanisms. Radionuclide tracers are required which are the source of detectable radiation. SPECT uses $\gamma$-radiation which is emitted by radioactive decay. In SPECT, a $\gamma$-decay is the source for the emission of a single $\gamma$-photon. In SPECT imaging, we are interested in the distribution process of a
tracer element within the human body. With the aid of γ-ray detectors, the source of activity, and thus the distribution of the target tracer in the body, is monitored. The implementation of a collimator guarantees that only photons perpendicular to the detector surface are registered, which allows the user to trace back the spatial origin of the photon. The measurement is conducted from different angles, and with a similar algorithm as used for CT, a 2D or 3D image can be reconstructed. The drawback of a collimator is the absorption of a large number of photons; thus, the SNR is much weaker compared to CT.

Positron emission tomography (PET) makes use of the β+ decay. A positron is emitted, which is the antimatter counterpart of an electron. When positron and electron collide, two γ-photons are emitted in opposite directions, which can be detected outside the body. A PET system contains many detectors that are placed in a circular arrangement around the patient. This enables the detection of γ-photons with precise spatial resolution. The arrival of both γ-photons at the specific detector location can be correlated, and the origin of the emission can be reconstructed. In this context, detailed technical information is available in the literature,48 and details about the application in clinical practice have been reviewed by Bateman.49 Generally, both techniques have large disadvantages with respect to spatial resolution compared to CT or MRI. However, the consequent analysis of tracer pathways enables the spatiotemporal representation of functional processes. Thus, PET or SPECT is also available as combined devices integrated in CT or MRI scanners (e.g., PET-CT or PET-MRI).

2.3.2. Contrast Agents in PET/SPECT. Tracers for SPECT are radionuclides that have a γ-decay channel. Important parameters are the half-life of the decay channel, the biological half-life, and the metabolomic pathway. Measurements of metabolomic pathways depend on the target molecule in which the tracer is embedded. Commonly used tracers are 123I, 111In, 67Ga, 201Tl, and 99mTc.50 Of particular interest is 99mTc because it is easily accessible in daily medical use. It can be derived from 99 Mo (which forms a so-called Technetium 99m generator). 99Mo has a half-life of approximately 66 h and can thus be easily transported to remote locations.

Tracers for PET, or PET radionuclides, can be found with low atomic number in isotopes of carbon, nitrogen, oxygen, or fluorine. The most common PET tracers are 11C and 18F.50 11C, especially, can easily be used to replace a naturally occurring carbon atom. Since carbon is basically the core element in biology, the replacement of the radio-silent 12C by the active 11C opens a vast range of possible tracer molecules. Since 12C and 13C are chemically equivalent, the measurement molecule does not affect the observed process, which yields an optimal measurement environment. In contrast, 18F is not abundantly available in many molecules. However, it can substitute a hydrogen atom as a biospecifical replacement without too much perturbation. Detailed analysis of different PET contrast agents can be found in the publication by Pimlott et al.50

2.4. Ultrasound Contrast Agents. 2.4.1. Contrast Concepts in Ultrasound. Compared to the previously discussed technologies, ultrasound is the simplest method with respect to instrumentation. Like MRI and CT, ultrasound has intrinsic contrast mechanisms. The physics of ultrasound is based on wave mechanics. Ultrasound technology uses the transmission of acoustic waves into tissue and the subsequent measurement of reflected waves. Two phenomena are important for reflection: First, different tissues have different wave impedance, which results in partial reflection of the wave at the interface of the adjacent tissues. Second, waves are scattered on little inhomogeneities and scattering bodies within a certain tissue type. If the wave impedance between two tissues differs extremely, then a large portion of the wave is reflected. This is for example the case at the interface of soft tissue and hard tissue or at the interface of soft tissue and air. In this case, a large amount of the wave is reflected. On one hand, we get a large signal from such interfaces; however, the volume behind this interface is obscured, because no energy is transmitted beyond this surface. Scattering depends on the tissue itself and is independent of interfaces. This phenomenon allows us to extract information from volumes between interfaces, e.g., from certain tissues or organs. A tissue with little or no scattering appears black, because there is no reflection and hence no information from this region. For example, blood or cavities filled with liquids appear dark. More technical details about ultrasound imaging are provided by Ortiz et al.51

2.4.2. Contrast Agents in Ultrasound. Contrast agents in ultrasound are tailor-made to increase the scattering in a target region. Thus, small inhomogeneities with respect to wave impedance are established in this specific region. To increase the affinity of a contrast agent to accumulate in a target region, active and passive targeting methods have been developed.52,53 Furthermore, the mechanical stability of the agent, the transition through capillaries, and physiological inertness are important parameters to characterize a contrast agent.54 Currently available contrast agents are small spheres composed of a thin shell made from phospholipids, proteins, or polymers and contain different gases. Gases which have been used so far include air, perfluoropropane, perfluorobutane, or sulfur hexafluoride.55 The diameter of spheres ranges from 1 μm up to 10 μm. There are many applications for contrast enhanced ultrasound imaging such as liver tumors, angiogenesis, or inflammatory disease.54

3. POLYSACCHARIDE-BASED THERANOSTICS

Polysaccharides, with a vast chemical assortment, inspire us to utilize their functional diversity. Besides, their extensive use in biomedical applications is conferred with imperative structural features, since they are essential components in biological systems.55 With the innovations in polymer science, polysaccharides can be engineered as biomedical tools with exclusive structures and distinctive functions. The intrinsic functional moieties associated with polysaccharides can act as attachment sites for therapeutic molecules, targeting ligands, and imaging probes via facile chemical amendments to impart sustained circulation time and site-specificity which are essential features for effective theranostic applications.56 The recent developments in polysaccharide-based nanomaterials have driven a new trend toward the development of multifunctional systems, which is dedicated in accomplishing theranostics applications with superior therapeutic efficacy, mechanical attributes, and satisfactory toxic profiles.57-63

Of late, extensive efforts have been made to develop theranostic systems for imaging guided cancer therapy with high efficiency while avoiding any unwanted side effects. In this regard, different nanomaterials such as metal nanoparticles (NPs), inorganic NPs, magnetic NPs, liposomes, micelles, carbon nanotubes, and quantum dots have been used as imaging agents in designing novel theranostic systems.55-65
Table 1. Overview of Some Recently Reported Polysaccharide-Based Theranostic Systems

<table>
<thead>
<tr>
<th>polysaccharides</th>
<th>source of extraction</th>
<th>drugs/imaging agents</th>
<th>synthesis strategy</th>
<th>properties</th>
<th>ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alginate</td>
<td>seaweed of brown algae</td>
<td>Doxorubicin (DOX)/iron oxide nanoparticles (INPs)/MRI</td>
<td>High loading efficiency (43%), Co-triggered release behavior, Minimal side effects to normal cells, High affinity to cancer cells</td>
<td></td>
<td>66</td>
</tr>
<tr>
<td>Alginate</td>
<td>seaweed of brown algae</td>
<td>PEI-coated manganese oxide nanoparticles (PEI-Mn3O4 NPs)/MRI</td>
<td>High r1 relaxivity of 26.12 mM⁻¹ s⁻¹ in vitro, Longer circulation time, Cytocompatibility</td>
<td></td>
<td>67</td>
</tr>
<tr>
<td>Chitosan</td>
<td></td>
<td>Curcumin/gold coated INPs/MRI</td>
<td>Ionic cross-linking of oleic acid coated INPs with chitosan</td>
<td>Enhanced ROS activity, Upregulation of γH2AX, p53 and p21 in the presence of blue light, T2 contrast property</td>
<td>68</td>
</tr>
<tr>
<td>Pectin</td>
<td>Citrus</td>
<td>Curcumin/gold coated INPs/MRI</td>
<td>−COOH group modified to −SH using mercaptopropanoic acid; Gold thiol chemistry</td>
<td>30% viability for HeLa cells, Enhanced ROS generation under γ-irradiation, r2 relaxivity in the range of 11.06–13.94 s⁻¹ μg⁻¹ mL⁻¹ in vitro</td>
<td>69</td>
</tr>
<tr>
<td>Alginate</td>
<td>seaweed of brown algae</td>
<td>Curcumin/gold coated INPs/MRI</td>
<td>−COOH group modified to −SH using L-cysteine; Gold thiol chemistry</td>
<td>Core−shell NPs of around 8.1 nm loading efficiency of 7.2 wt %</td>
<td>70</td>
</tr>
<tr>
<td>Dextran</td>
<td>Lactic acid bacteria</td>
<td>Carboxymethyl dextran coated INPs/MRI</td>
<td>Coprecipitation</td>
<td>One pot synthesis, Utility for functional and structural MRI</td>
<td>71</td>
</tr>
<tr>
<td>Dextran</td>
<td>Lactic acid bacteria</td>
<td>Epichlorohydrin (ECH) stabilized dextran coated INPs/MRI</td>
<td>Epoxy group of ECH cross-linking with −OH group of dextran</td>
<td>Internalization by macrophages, Absence of hypersensitivity on pig model, r2 relaxivity ranging 46.8–207.4 mM⁻¹ s⁻¹ in vitro, High resolution of cartilage and lesion MR images</td>
<td>72</td>
</tr>
<tr>
<td>Hyaluronic acid (HA)</td>
<td>Animal tissues</td>
<td>Gadolinium (Gd)-Diethyleneetriaminepentaacetic dianhydride (DTPA)-HA/MRI</td>
<td>−OH group of HA and −COOH group of DTPA react via ring opening reaction followed by cross-linking with Gd</td>
<td>r1 relaxivity of 12.51 mM⁻¹ s⁻¹ in vitro, High resolution of cartilage and lesion MR images</td>
<td>73</td>
</tr>
<tr>
<td>HA</td>
<td>Animal tissues</td>
<td>Gd-peptide Dendron-HA/MRI</td>
<td>Azide modified Dendron−Gd complex−COOH modified HA with alkynyl group using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM); Click chemistry</td>
<td>r1 relaxivity of 7.7 mM⁻¹ s⁻¹ in vitro, Retention of the system at tumor site in vivo, High hemocompatibility, Efficient DNA carrier, Enhanced transfection efficiency</td>
<td>74</td>
</tr>
<tr>
<td>HA</td>
<td>Animal tissues</td>
<td>Superparamagnetic INPs (SPIONs)-Poly-L-Lysin-HA/MRI</td>
<td>−COOH group of HA reacts with −NH2 group of aminoethyl cholanomide; EDC/NHS Cross-linking</td>
<td>Efficient DNA carrier, Enhanced transfection efficiency</td>
<td>75</td>
</tr>
<tr>
<td>Dextran</td>
<td>Lactic acid bacteria</td>
<td>supramolecular amorphous-like iron oxide (SAIO)/MRI</td>
<td>Supramolecular assembly</td>
<td>Relaxivity-coefficient ratio of ~1.2 in vitro, Long blood circulation, Satisfactory renal clearance, pH-dependent drug release profile</td>
<td>76</td>
</tr>
<tr>
<td>Carboxymethyl cellulose (CMC)</td>
<td>Plant origin</td>
<td>L-dopa/Cobalt−copper doped manganese ferrite (CCMn) nanorods/MRI</td>
<td>Simple chemical reaction</td>
<td>CMC coated CCMn nanorods, Simple chemical reaction</td>
<td>77</td>
</tr>
</tbody>
</table>
These nanomaterials have been combined with various natural polymers such as polysaccharides that act as a carrier matrix in theranostics and cancer immunotherapy. These polymeric matrices help to achieve better solubility and biodistribution of drugs and with renal clearance, crossing biological barriers, and avoiding drug degradation. Additionally, the natural polymer matrix also helps in high drug loading and tuning its release under complex biological conditions. The combination of imaging and drug delivery achieved by these systems helps in anticipating the patient’s response to treatment which can be tailored for personalized therapy. Table 1 provides an overview of some recently reported polysaccharide-based theranostic systems with a detailed outline of the fabrication process and key features. Further, in this section, we will discuss various polysaccharide/nanomaterial-based systems for imaging guided cancer therapy.

### 3.1. Theranostic Systems with MR Imaging Feature

High contrast MR images can be obtained by increasing the $T_1$ relaxivity of the contrast agent system which in turn is affected by molecular tumbling rate ($\tau_r$). The slower the molecular tumbling rate, the higher the $T_1$ relaxivity will be. To decrease the tumbling rate of complexes used in MRI and to obtain high contrast images, these complexes are conjugated with various polymers which increases the overall molecular weight of the system. Apart from decreasing the molecular tumbling rate, the use of polymer matrix also provides the possibility of loading various drugs to develop multifunctional theranostics.

In this regard, polysaccharide matrix-based theranostics for MR imaging and simultaneous/sequential drug delivery are gaining increasing interest due to low cost of polysaccharides, a variety of available functional groups for post-modification, biocompatibility, biodegradability, and especially higher in vivo residence time. This higher residence time is a result of the adhesion of polysaccharide to mucosal surfaces and decreased uptake by phagocytes. On the other hand, gadolinium (Gd)-based contrast agents provide positive $T_1$-weighted MR images but suffer from low relaxivity and short residence time. To address this issue, Gd-based contrast agents have been combined with polysaccharides and nanomaterials. For example, Liu et al. fabricated MoS$_2$ nanosheets which were decorated with amine-functionalized hyaluronic acid. Next, the diethylenetriaminepentaacetic acid (DTPA) linker was used to load Gd$^{3+}$ ions and combine them with hyaluronic acid functionalized MoS$_2$ nanosheets. Afterward, an anticancer drug gefitinib was loaded, and the developed system was investigated in vivo for its MRI properties. The reported theranostic system was found to have 3.3 times higher relaxivity as compared to commercially available Gd-DTPA contrast agent. Further, the system could effectively convert near-infrared light to heat, causing both a photothermal effect and a release of gefitinib resulting in cell apoptosis in a mouse model having lung cancer (Figure 2). In this way, the developed system could provide the possibility of combining multiple actions including MRI, drug delivery, and photothermal therapy. Further, Cavalli et al. designed chitosan-based nanobubbles (~500 nm) loaded with Gd-DOTP as $T_1$ MRI contrast agent and prednisolone phosphate as a model drug. A sustained drug release could be achieved by ultrasonic treatment with enhanced $T_1$ contrast properties owing to the presence of a chitosan shell.

To develop a Gd$^{3+}$-based safe theranostic system exhibiting no leakage of the contrast agent, Podgorna et al. created Gd$^{3+}$-loaded alginate nanogels (110 nm) via an inverse mini-emulsion method. The developed nanogels were further modified by using chitosan and alginate via a layer-by-layer technique, and rhodamine B was used as a model drug. The Gd$^{3+}$-loaded alginate nanogels exhibited reduced $T_1$ relaxation time. The samples were found to be stable for 2 months with no leaching of Gd$^{3+}$ ions during this time, thus showing their potential for clinically safe theranostics.

To obtain a theranostic system with enhanced $T_1$ contrast efficiency, Wang et al. explored chitosan modified graphene oxide nanosheets as a single nanocarrier for drug delivery and MR imaging. Herein, chitosan-modified reduced graphene oxide nanosheets were loaded with SPION acting as contrast agent and doxorubicin (DOX) as an anticancer drug. MRI experiments confirmed the potential of the developed system to be used as a $T_2$ contrast agent with predominant accumulation in cancer cells. Further, DOX could also be released under the acidic environment present in cancer cells showing that these SPION and DOX-loaded chitosan-modified reduced graphene oxide nanosheets could be used as an effective theranostic system. In this direction, the drug release
efficiency and $T_2$ contrast efficiency can also be tuned by adjusting the molecular weight of chitosan. Baktash et al. reported that drug delivery could be increased by decreasing the molecular weight of chitosan attached to magnetic

Figure 3. Schematic representation for the fabrication of paclitaxel (PTX)-loaded PTPMNs (a); magnetic resonance images of PTPMNs in phantom gel (b); $T_2$ relaxation decay curves for PTPMNs (c); cytotoxicity of free PTX, PTPMNs, and PTX loaded PTOHMNs against PLC/PFR/S cells (d). Adapted with permission from ref 89. Copyright 2020 Elsevier Ltd.

Figure 4. Scheme showing accumulation of alginate microgels in a tumor. Alginate microgels are cross-linked with holmium ions ($T_3$ MRI agent) and contain temperature-responsive liposomes having fluorescein and $[\text{Gd(HPDO3A)(H}_2\text{O)}]$ as a $T_1$ MRI contrast agent. In response to temperature (mild hyperthermia), both drug and $T_1$ contrast agent can be released. Reproduced with permission from ref 90. Copyright 2015 Elsevier Ltd.
graphene oxide nanosheets due to lower hydrogen bonding and π-π interactions. On the other hand, increasing the molecular weight of chitosan helped in increasing T2 contrast efficiency by providing efficient coverage of the surface. Similarly, DOX and SPION loaded poly(L-arginine chitosan triphosphate)-based theranostic nanoparticles were developed by Gholami et al. via an ionic gelation method. pH-responsive DOX release was observed achieving the efficient killing of glioblastoma cells. MRI studies confirmed that the increasing iron content in the developed nanoparticles could effectively enhance the T2 MRI contrast signal. The mentioned studies clearly reveal how the drug release and MR properties of the developed theranostics systems can be tuned by varying different parameters related to both polymer matrix and imaging agent.

Further, taking advantage of the low toxicity of gold-coated Fe3O4 nanoparticles reported in the literature, Arora et al. designed plasmonic magnetic nanoparticles decorated with partially modified sodium alginate. Herein, thiolated sodium alginate (TSA) was hydrophobized by grafting amine-functionalized poly(butyl methacrylate) (PBMA). The modified sodium alginate was further used to stabilize gold-coated Fe3O4 nanoparticles (PTPMNs). PBMA grafted TSA helped in loading the hydrophobic drug paclitaxel (PTX) with increased loading efficiency (Figure 3a). Loaded drug could be successfully delivered at the target cancer site owing to the breaking of disulfide bonds under the reducing conditions. Additionally, the developed system acted as a negative contrast agent for MRI providing darker images with increasing amounts of iron in the sample (Figure 3b). T2 decay curves in the iron concentration range 0.5−50 μg/mL exhibited faster relaxation with increasing iron in the phantom gel (Figure 3c).

Cytotoxicity experiments demonstrated the higher killing efficiency of PTX loaded PTPMN as compared to free PTX against PLC/PRF/S cells (Figure 3d), thus providing the possibility of imaging-guided cancer therapy.

Taking a step further, van Elk et al. fabricated temperature-sensitive liposomes containing alginate microgels to develop a theranostic system capable of performing both T1 and T2 MRI along with controlled drug delivery. Here, the liposomes were loaded with fluorescein as a model drug and Prohance [Gd(HPDO3A)(H2O)] as a T1 MRI contrast agent. Further, alginate microgels having liposomes were prepared by cross-linking with holmium ions which acted as T2 MRI contrast agent (Figure 4). The developed system was found to be colloidally stable and could be successfully used for real-time, imaging-guided therapy in vivo.

In the quest to develop new theranostic systems, Nejadshaifie et al. developed a magnetic metal organic framework (MOF) nanocomposite-based theranostic system capable of delivering multiple drugs. Herein, magnetic Fe3O4 nanoparticles containing MOF with Zn2+ ions and curcumin drug were developed. The magnetic MOF nanocomposite was further functionalized with folic acid containing chitosan for targeted delivery and loaded with S-fluorouracil (S-FU) drug. The developed nanocomposite acted as a robust theranostic system exhibiting controlled release of both curcumin and S-FU along with enhanced T2 MRI contrast in cancer cells. To further explore the potential of MOF-based theranostics for multimodal imaging and drug delivery, Lin et al. designed carbon dots embedded MOF@O-carboxymethyl chitosan nanoparticles. The use of O-carboxymethyl chitosan in fabricating the particles provided pH-responsive release of doxorubicin. The developed system could be used for dual-imaging including fluorescence and T2 MRI.

Apart from the contrast agents discussed above, MnO2 nanomaterials have also gained significant interest for addressing the demand of new theranostic alternatives. For example, Li et al. used a porous coordination network MOF (PCN-224), which in turn was coated with a MnO2 shell. Further, PCN-224@MnO2 were loaded with doxorubicin drug followed by functionalization with hyaluronic acid PCN@MnO2@DOX@HA. Hyaluronic acid helped in binding with CD44 receptors overexpressed on tumor cells, while in the presence of GSH, DOX was released and MnO2 generated Mn2+ which could be used as T1 MRI contrast agents. Furthermore, MnO2 could catalyze the conversion of H2O2 present in cells to O2 resulting in the reduction of tumor hypoxia, which in turn could be helpful for increasing the efficiency of cancer therapy. Similarly, to address the issue of reactive oxygen species affecting the efficiency of radio-chemotherapy, and to achieve combined therapeutics delivery and MRI imaging, Zhao et al. reported flower-like MnO2 nanoparticles modified with hyaluronic acid. The particles were further loaded with H2PtCl6, which acts as an inhibitor for tumor cell proliferation. The efficiency of H2PtCl6 loading was enhanced here due to the presence of hyaluronic acid. The developed system also acted as a radiosensitizer, thus providing the possibility of combining radiotherapy with imaging and therapeutics delivery. It is to be noted here that although MnO2 nanomaterials-based contrast agents have been frequently explored in the literature, very limited studies have been performed so far by using them in combination of natural polymers providing a less explored platform for new theranostics.

In summary, various theranostic systems with tunable properties have been developed in recent years using different polysaccharides such as dextran, pullulan, gelatin, starch, cellulose, heparin, and hyaluronic acid. Table 2 provides an overview of recent examples of polysaccharides based theranostic systems that have been reported in the literature for combined drug delivery and MRI.

3.2. Theranostic Systems with CT Imaging Feature. In recent years, extensive efforts have been made to develop novel contrast agents for CT imaging that help in getting better contrast between the adjacent tissues, thus helping in better diagnosis. In this regard, gold NPs have come up as an ideal candidate owing to the higher density and higher atomic number of gold. To enhance the stability of gold NPs, their surface is modified with biocompatible small molecules or macromolecules. Although the surface modification of gold NPs with polyethylene glycol (PEG) improves their stability, the particles are not stable in the presence of GSH and high salt concentration. Additionally, the coating with PEG hinders the cellular uptake of the developed modified NPs. To address these issues, Sun et al. fabricated glycol chitosan (GC) modified gold NPs (GC-AuNP) showing stability and remarkable cancer targeting features owing to the presence of GC. The particles were also conjugated with peptides which could be activated by matrix metalloproteinase (MMP). The developed MMP-GC-AuNP provided the possibility of having optical imaging in combination with CT imaging (Figure 5). It is to be noted here that having the targeting feature in a CT probe is extremely beneficial, and the use of different polysaccharides plays an important role in it. Hence, to further understand the importance of surface modification using GC,
Table 2. Overview of Recent Examples of Polysaccharide-Based Theranostics

<table>
<thead>
<tr>
<th>Sample</th>
<th>Poly saccharides</th>
<th>Contrast agent</th>
<th>Therapeutics</th>
<th>Imaging</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Chitosan</td>
<td>Fe&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt; NPs</td>
<td>Nanoceria</td>
<td>T&lt;sub&gt;2&lt;/sub&gt; MRI</td>
<td>Electrostatic self-assembly and ion gelation approaches; self-assembly based theranostics less cytotoxic as compared to ionic gellation; ROS scavenging capability</td>
</tr>
<tr>
<td>2</td>
<td>Chitosan</td>
<td>Gd&lt;sup&gt;3+&lt;/sup&gt;</td>
<td>Chlorin e6</td>
<td>T&lt;sub&gt;1&lt;/sub&gt; MRI</td>
<td>Chitosan conjugated with octadecanoyl acid and gadopentetic acid; self-assembly approach, negligible hemolysis and satisfactory ROS generation</td>
</tr>
<tr>
<td>3</td>
<td>Chitosan</td>
<td>Fe&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt; NPs (MRI); Au NPs (CT)</td>
<td>Methotrexate</td>
<td>T&lt;sub&gt;1&lt;/sub&gt; MRI</td>
<td>Surface coating with modified chitosan; good cytocompatibility; magnetic property and X-ray attenuation</td>
</tr>
<tr>
<td>4</td>
<td>Metal organic framework@chitosan</td>
<td>MIL-100 (Fe-BTC); Carbon dots</td>
<td>Doxorubicin</td>
<td>Dual T&lt;sub&gt;2&lt;/sub&gt; MRI and optical imaging</td>
<td>Coating with O-carboxymethyl chitosan for improved biocompatibility and pH responsive drug release</td>
</tr>
<tr>
<td>5</td>
<td>Sodium alginate</td>
<td>Proflavine [Gd (HPD303A)(H&lt;sub&gt;2&lt;/sub&gt;O)]; Holmium ions</td>
<td>Fluorescein</td>
<td>T&lt;sub&gt;1&lt;/sub&gt; MRI; T&lt;sub&gt;2&lt;/sub&gt; MRI</td>
<td>Cross-linking by holmium metal ions, temperature responsive drug release</td>
</tr>
<tr>
<td>6</td>
<td>Sodium alginate</td>
<td>Fe&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt; NPs</td>
<td>Paclitaxel</td>
<td>T&lt;sub&gt;1&lt;/sub&gt; MRI</td>
<td>Coating with thiolated sodium alginate grafted with amine-terminated poly(butyl methacrylate); enhanced dispersion stability and drug encapsulation efficiency</td>
</tr>
<tr>
<td>7</td>
<td>Sodium alginate</td>
<td>Gd&lt;sup&gt;3+&lt;/sup&gt;</td>
<td>Rhodamine b</td>
<td>T&lt;sub&gt;1&lt;/sub&gt; MRI</td>
<td>Alginate nanogel by reverse microemulsion and physical cross-linking; enhanced stability; presence of alginate reduces the T&lt;sub&gt;1&lt;/sub&gt; relaxation time</td>
</tr>
<tr>
<td>8</td>
<td>Disulfide modified alginate</td>
<td>Fe&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt; NPs</td>
<td>Doxorubicin</td>
<td>T&lt;sub&gt;1&lt;/sub&gt; MRI</td>
<td>Covalent binding of Fe&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt; NPs with disulfide modified alginate; pH and reducing environment responsive drug release; lower side effects to healthy cells</td>
</tr>
<tr>
<td>9</td>
<td>Gelatin</td>
<td>Silica coated Fe&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt; NPs</td>
<td>Paclitaxel and taxol</td>
<td>T&lt;sub&gt;1&lt;/sub&gt; MRI</td>
<td>Coating with gelatin oleic acid; enhanced circulation time and regulated transportation of paclitaxel to tissues</td>
</tr>
<tr>
<td>10</td>
<td>Hyaluronic acid</td>
<td>Fe&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt; NPs</td>
<td>Homocamptothecin</td>
<td>T&lt;sub&gt;1&lt;/sub&gt; MRI</td>
<td>Covalent conjugation of hyaluronic acid; accumulation in tumor tissue under the magnetic field; enhanced biocompatibility</td>
</tr>
<tr>
<td>11</td>
<td>Alginate, chitosan</td>
<td>Fe&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt; NPs, Au NPs</td>
<td>Gene delivery</td>
<td>Dual MRI and CT imaging</td>
<td>Assembly of alginate/chitosan polyelectrolyte in multilayer on metal NPs; enhanced stability and biocompatibility; pH responsive drug release; enhanced cell apoptosis</td>
</tr>
<tr>
<td>12</td>
<td>Catechol-grafted chitosan algin-ate</td>
<td>Barium sulfate microcapsule</td>
<td>Ranitidine hydrochloride</td>
<td>CT imaging</td>
<td>Self-assembly of catechol grafted chitosan on microcapsules; enhanced retention in stomach;</td>
</tr>
<tr>
<td>13</td>
<td>Glycol chitosan</td>
<td>Iodine-containing dia- troxic acid, perfluoropentane</td>
<td>-</td>
<td>Dual CT and ultrasound imaging</td>
<td>Chemical conjugation of iodine to glycol chitosan; physical encapsulation of perfluoropentane by emulsification</td>
</tr>
<tr>
<td>14</td>
<td>Chitosan</td>
<td>Au nanocluster</td>
<td>MPP-9 Plasmid shRNA</td>
<td>CT imaging</td>
<td>Azide–alkyne cyclization reaction for preparing chitosan-grafted-poly(s-lysine); surface coating of modified chitosan; enhanced CT signal in comparison to commercial iohexol; enhanced plasmid delivery</td>
</tr>
<tr>
<td>15</td>
<td>Chitosan</td>
<td>Au nanorattle</td>
<td>Doxorubicin; photothermal therapy</td>
<td>SERS based imaging</td>
<td>NIR-responsive drug delivery, ROS generation; induces membrane blebbing</td>
</tr>
<tr>
<td>16</td>
<td>Chitosan/hollow meso po-rous silica nanoparticles</td>
<td>CuS nanodots</td>
<td>Doxorubicin; photothermal therapy</td>
<td>Thermal/photoacoustic dual-modality imaging</td>
<td>NIR and reducing environment responsive drug delivery</td>
</tr>
<tr>
<td>17</td>
<td>Hyaluronic acid</td>
<td>WS&lt;sub&gt;2&lt;/sub&gt; nanodots, Ce6</td>
<td>Photothermal, radiation, photodynamic combina- tion therapy</td>
<td>Multimodal CT, Fluorescence, photoacoustic imaging</td>
<td>Hyaluronic acid/polyaniline hybrid shell on nanodots; enhanced tumor uptake; higher efficiency for radiation and photodynamic therapy</td>
</tr>
<tr>
<td>18</td>
<td>Hyaluronic acid</td>
<td>Molybdenum oxide NPs</td>
<td>Photothermal therapy</td>
<td>CT imaging</td>
<td>Improved precision of phototherapy by combination of CD44 receptor targeting and tumor microenvironment related pH responsiveness</td>
</tr>
<tr>
<td>19</td>
<td>Dextran</td>
<td>Iodine</td>
<td>Doxorubicin</td>
<td>CT imaging</td>
<td>Hydrogel microspheres via inverse suspension polymerization method; potential interventional embolization</td>
</tr>
<tr>
<td>20</td>
<td>Dextran</td>
<td>Poreus silicon; Au NPs</td>
<td>XMU-MP-1</td>
<td>CT imaging</td>
<td>Microfluidic method enables the incorporation of multiple NPs together in a single step; identification of pathological changes in liver tissue; improved drug solubility and drug function during as compared to free drug</td>
</tr>
<tr>
<td>21</td>
<td>β-Cyclodextrin-based poly (ε-caprolactone)-dextran star polymer</td>
<td>Fe&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt; NPs</td>
<td>Doxorubicin</td>
<td>T&lt;sub&gt;1&lt;/sub&gt; MRI</td>
<td>Reducing environment responsive drug delivery; folate receptor mediated endocytosis</td>
</tr>
<tr>
<td>22</td>
<td>Chitosan</td>
<td>Fe&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt; NPs</td>
<td>-</td>
<td>T&lt;sub&gt;1&lt;/sub&gt; MRI</td>
<td>8-fold increase in transverse relaxivity rate (r&lt;sub&gt;2&lt;/sub&gt;) reaching a maximum of 533 Fe mM&lt;sup&gt;−1&lt;/sup&gt; s&lt;sup&gt;−1&lt;/sup&gt;</td>
</tr>
<tr>
<td>23</td>
<td>Chitosan</td>
<td>Au NPs</td>
<td>Photothermal therapy</td>
<td>Photoacoustic imaging</td>
<td>Synergistic gene/photothermal therapy for breast cancer</td>
</tr>
<tr>
<td>24</td>
<td>Dextran or pullulan</td>
<td>Au nanorods</td>
<td>-</td>
<td>Photothermal therapy</td>
<td>Capability of responsive self-destruction</td>
</tr>
</tbody>
</table>
Sun et al. compared the tumor-targeting behavior of GC-AuNP and heparin-coated gold NPs. It was reported that heparin-coated gold NPs were accumulated in normal tissue of the liver, while GC-AuNP targeted the tumor site. Experimental results further indicated that accurate CT images could be obtained for liver cancer cells using GC-AuNP. Additionally, the presence of an amine group on the surface could also be explored for drug conjugation.

Similarly, to develop an efficient CT-guided chemotherapy system, Keshavarz et al. synthesized alginate hydrogels loaded with gold NPs and cisplatin drug. CT studies showed the increased CT contrast exhibited by the developed system. Cytotoxicity experiments exhibited higher tumor cell killing efficiency of gold NPs and cisplatin drug-loaded alginate hydrogels as compared to free drug. On the other hand, Li et al. synthesized gold-coated Fe$_3$O$_4$ nanostars stabilized by hyaluronic acid, which could be successfully used for dual CT and MR imaging in vivo.

Further, cellular uptake of the nanoparticles is not only influenced by their size but also by their shape. It has been reported that the particles having higher aspect ratio can be internalized more readily than spherical ones. Hence, to explore the potential of nonspherical contrast agents in multifunctional therapy, Hu et al. used spindle-shaped cellulose nanocrystals which were modified with synthetic polymer-based heterogeneous polymer brushes. The surface-modified cellulose nanocrystals were further used as a template for in situ growth of gold NPs. The developed system was successfully used for CT imaging and gene therapy displaying its capability for multiple actions in treatment.

In another direction, research attempts have also been made to develop the CT contrast agent via a green chemistry method for targeted imaging. In this regard, Uthaman et al. synthesized mannan-functionalized gold NPs (M-GNPs) by using mannan as both a reducing and stabilizing agent. Mannan is a bioactive polysaccharide which helped here in avoiding the use of external reducing agents such as NaBH$_4$. The overall synthesis was based on a green approach without involving any harmful chemical or solvent. The developed M-GNPs could target the lymph nodes and were effectively taken up by endocytosis with the help of mannan receptors expressed on the surface of cells. M-GNPs were efficient as a CT imaging probe with maximum Hounsfield units of 303. The increasing accumulation of M-GNPs in lymph nodes as a function of time was also investigated with the help of silver-eosin staining. It was reported that M-GNPs are selectively taken up by the macrophages and dendritic cells due to the presence of mannan receptors. In this way, the developed M-GNPs showed their potential for selective lymph node targeted CT imaging which is an active area of research.

In their quest to explore other inorganic NP-based CT contrast agents, Du et al. prepared hyaluronic acid-coated Bi$_2$O$_3$ NPs for CT imaging. Due to the presence of hyaluronic acid, the developed NPs were very stable and able to bind effectively to CD44 receptors overexpressed on the cancer cells. Hyaluronic acid-coated Bi$_2$O$_3$ NPs showed multiple activities by exhibiting efficient attenuation of X-rays along with providing radiosensitization causing cell apoptosis. In this way, the developed system could be a potential candidate for CT imaging guided radiotherapy of tumors due to the low cost of bismuth element as compared to gold and higher radiosensitization.
tungsten trioxide NPs are also able to attenuate X-rays with high efficiency. However, few studies have reported the application of theranostics by combining polysaccharides with bismuth and tungsten-based nanoparticles due to the lack of functional groups for post-modification and difficulty in controlling their shape and size.

Apart from inorganic nanoparticles providing CT contrast, iodine-based low-molecular-weight molecules have also been used for CT imaging. As iodinated molecules are non-target-specific and exhibit lower retention time, it is difficult to obtain high-contrast images in short imaging time. Hence, these small molecules have been used in combination with functional polymers to obtain desirable pharmacokinetics and target specific high contrast images. In this regard, Zhu et al. prepared HAI-NGs for breast cancer-targeted CT imaging and chemotherapy. Herein, HAI-NGs were prepared by click reaction-based photo-cross-linking of the disulﬁde linkage containing polyiodixanol-methacrylate and hyaluronic acid-cystamine-tetrazole. Further, paclitaxel anticancer drug was loaded in the developed nanogels for efﬁcient chemotherapy. This paclitaxel-loaded HAI-NGs exhibited remarkable targeting ability for CD44 receptors and could degrade under the reducing conditions of cancer cells (Figure 7b,c). The circulation time of the contrast agent was effectively increased as compared to free iodinated molecules, thus presenting itself as a novel theranostic system for imaging guided therapy.

Similarly, Lee et al. synthesized 2,3,5-triiodobenzoic acid-conjugated hyaluronic acid which self-assembled into multifunctional nanoparticles. These NPs were loaded with doxorubicin as a model anticancer drug. Once again, the interaction between hyaluronic acid and CD 44 receptor was exploited here to ensure the uptake of developed nanoparticles by cancer cells. High-contrast CT images could be obtained in a SCC7 tumor-xenografted mouse model due to the presence of iodinated components in the NPs. Further, fluorescent dye Cy5.5 was also attached to the system to allow the possibility...
of near-infrared (NIR) fluorescence imaging, thus achieving multimodal imaging and chemotherapy.\textsuperscript{137}

To investigate CT contrast alternatives apart from iodine-based molecules, Liang et al. synthesized multifunctional NPs using hyaluronic acid conjugated with two NIR dyes (Cy5.5 and IR825).\textsuperscript{138} These NPs were loaded with perfluorooctyl bromide (PFOB), which in turn acted as CT contrast agent. Here, Cy5.5 provided fluorescent imaging, while IR825 provided the opportunity for photoacoustic imaging. Thus, the developed hyaluronic acid-based theranostic NPs showed multimodal imaging action for effective diagnosis. Various recent examples of theranostics systems, including a CT imaging feature, prepared by using a polysaccharide-based polymer matrix have been summarized in Table 1.
3.3. Theranostic Systems with PET/SPECT Imaging Feature. Early and precise diagnosis of cancer information is vital to construct the optimal treatment plan. Significant efforts are being made for advancement in fluorescent and radionuclide-based diagnostic tools which are helpful in cancer diagnosis. In comparison to fluorescent imaging, nuclear/radionuclide imaging provides precise information with infinite penetration depth and also offers quantitative capability.

Of late, natural polymer-based complexes (nanoparticles and nanocrystals) and hydrogels tagged with radionuclides have shown remarkable potential in SPECT/PET-based imaging (Figure 8). Metal-chelating properties of natural polymers have been explored by many researchers in cross-linking biopolymer-based hydrogels with radiometal cations to support noninvasive tumor imaging with SPECT/PET. In order to design imaging probes for clinical applications, facile synthetic routes, uniformity, reproducibility, capability for scaleup, biosafety, and colloidal stability are some key aspects which need to be addressed.

Alginate is an important class of natural polymers and has been extensively explored for its role in various biomedical applications. Cross-linked alginate hydrogels have been widely used to mimic soft tissues. However, these hydrogels have also been associated with limitations of being detected by various imaging platforms like MRI, SPECT, and PET. To address these shortcomings, Patrick et al. tested the capability of InCl₃ and ZrCl₄ in cross-linking alginate to aid imaging of ¹¹¹In and ⁸⁹Zr with the help of SPECT and PET, respectively (Figure 8). The work targeted 3D noninvasive nuclear imaging platform with good resolution across the anatomy and can be used for both preclinical and clinical trials. This system offered the possibility to image the whole body at the in vivo level by analyzing the retention and clearance of alginate-based hydrogels used in drug delivery via nasal and oral routes of administration. The work also demonstrated the colocalization of ¹¹¹In-alginate with mesenchymal stem cells (MSCs) at the site of implantation with in-depth biodistribution. This study emphasized the repeatability and long-term stability of the designed system as a key aspect to attain effective theranostic applications.

Further, Gholipour et al. developed a ⁶⁸Ga-dextran complex (GaD) for dual-modality PET/MRI imaging. The efficacy of the designed complex was tested under both acidic and alkaline conditions. The in vivo biodistribution of the fabricated GaD complex displayed its enhanced accumulation in the lungs with a substantial uptake that was detected in the cartilage tissues as well. On the other hand, Keliher et al. developed a zirconium-⁸⁹ (⁸⁹Zr) cross-linked short-chain dextran nanoparticle for a macrophage-specific PET imaging agent. With a half-life of 3.9 h, the designed system was found to be mainly located in tissue-resident macrophages when compared to other WBCs. These strategies offered reproducibility, colloidal stability, and biosafety along with versatility to be used for various imaging platforms.

The microenvironment around a tumor is very difficult to categorize, and in order to gain a significant understanding regarding its structure and developmental mechanism, nanoparticles have played an important role. Nanoparticles of varied shape and size are ideal candidates to combine drug delivery with imaging techniques such as PET/SPECT for proficient cancer therapy. In a study, Imlimthan et al. developed Lutetium-¹⁷⁷ (¹⁷⁷Lu)-labeled cellulose (LuC) nanocrystals loaded with vemurafenib as a multifunctional platform for drug delivery and noninvasive diagnosis of melanoma using SPECT imaging. LuC nanocrystals were investigated for their immunological behavior in murine and human melanoma cells. The efficacy of LuC nanocrystals was also analyzed in a mouse model bearing melanoma allografts in the lung. The LuC nanocrystals offered complementary radiolabel stability, better drug release profile, cellular uptake, and inhibition of cell growth at the in vitro level. The biodistribution of LuC nanocrystals in vivo revealed substantial retention of the LuC nanocrystals in the lung, liver, and spleen. The results obtained for LuC nanocrystal-based SPECT imaging could have a fascinating future in potential clinical applications.

Researchers have developed and utilized a variety of polymer-based platforms for multimodal imaging applications. Consistent efforts to develop even more sophisticated polymer-based imaging probes have been the driving force for many research groups. The versatility of chitosan has identified it as a potential biopolymer in many theranostic applications. Hwang et al. developed ¹³¹I-labeled chitosan hydrogels for theranostic applications for liver cancer. SPECT was utilized to study the tumor induction rate, which was reported to be around 72% with major accumulation of ¹³¹I-labeled chitosan observed in the liver. The system offered negligible extrahepatic deposition and provided evidence for a new class of radioembolization devices with substantial therapeutic potential for MR/SPECT-based imaging applications. In another study, Pang et al. developed a chitosan–collagen-based composite microsphere (CCM) and radiolabeled it with Iodine-131 (¹³¹I) for hepatocellular carcinoma (HCC) treatment. With a high processed efficiency of 70.4 MBq mg⁻¹ of microspheres, the system also offered colloidal stability at the in vitro level. The designed system could be used for dual-imaging applications with regression in tumor size as indicated through SPECT/MR imaging. Adequate localized biodistribution upon administration along with steady stability of ¹³¹I-CCMs in the liver over a period of 28 days showed the competence of ¹³¹I-CCMs as a probable candidate for cancer theranostics.

On similar grounds, Lee et al. radiotagged ⁶⁴Cu to chitosan (CuC) nanoparticles through click chemistry via a strain-promoted azide–alkyne cycloaddition strategy with a high radiolabeling efficiency and yield of almost 98%. Adequate colloidal stability and negligible effect on the physicochemical properties (zeta potential, spherical morphology) of chitosan were added advantages associated with the designed system. Upon intravenous administration of CuC nanoparticles in tumor-bearing mice, tumor targetability and real-time in vivo biodistribution were analyzed with the help of micro PET. Facile synthetic route and higher yield marked the potential of this system as a potent tool for PET-based tumor imaging.

To impart multimodal imaging ability, thereby enhancing the versatility of chitosan, Lee et al. fabricated a dual-mode imaging probe for PET/optical imaging based on glycol chitosan nanoparticles (CNPs). To fabricate the dual PET/optical probe based on CNPs, both ⁶⁴Cu-radiolabeled DOTA complex and activable matrix metalloproteinase (MMP)-sensitive peptide were tagged onto CNPs with the help of bio-orthogonal click chemistry through chemically reacting azide group and dibenzyl cyclooctyne. In vivo biodistribution and the expression of MMP-sensitive peptides were monitored in tumor-bearing mice with the help of PET/optical imaging. Further, Polyak et al. manufactured poly(γ-glutamic acid)-based dual modality imaging probes for PET/SPECT/cum with good uptake and biodistribution in vitro and in vivo. These studies have shown that these systems have huge potential for efficient cancer therapy in the future.
acid)/folic acid/chitosan-based self-assembled nanoparticles with high colloidal stability and radiolabeled them with technetium-99m ($^{99m}$Tc). The system was studied for its potential as an effective SPECT/CT imaging agent in order to diagnose tumors with augmented levels of folate receptors. The results concluded that there was enhanced activity along with slow elimination from the heart, liver, kidneys, and urinary tract. \(^{163}\) Extensively higher uptake (9% of administered dose) was recorded for the HeDe (Hepatocarcinoma Debreceniensis) tumor cell line transplanted Fischer 344 rat models compared to 2% in control rat models. The study suggested the potential of using the fabricated system for clinical translation. Collectively, the studies revealed the fact that in order to design an effective and efficient PET/SPECT agent, the imaging time frame after dose administration plays a key role. This factor could be applied for further investigation in order to amend the existing polymer-based systems in order to develop more sophisticated and efficient imaging-based clinical applications.

To investigate the folate receptor-targeted radionucleotide-tagged agent for multimodal imaging for detecting ovarian cancer cells, Korhegyi et al. developed modified folic acid nanoparticles and conjugated them with chitosan-modified chelator (NODAGA-NHS) followed by radiolabeling with Gallium-68 ($^{68}$Ga) (III) ions. PET/MR dual imaging showed enhanced tumor uptake with a 6.5 tumor-to-muscle ratio. \(^{164}\) Selective binding of the designed nanoparticles was observed at an in vitro level in folate receptor-positive (KB) and negative (MDA-MB-231) cell lines. Subcutaneous administration on tumor-bearing CB17 SCID mice models provided significant uptake of the nanoparticles at an in vivo level as studied by PET/MR dual imaging. These examples clearly indicate the potential of chitosan in the development of radionucleotide-tagged systems for SPECT/PET imaging.

The cited examples and studies given above shows the importance of chitosan in development of imaging probes for SPECT/PET imaging. Further, natural polymers like dextran, hyaluronic acid, and heparin have significant target abilities and because of less complexity and low molecular weight could easily be maneuvered and controlled for theranostic applications. This could provide room for further investigation in an attempt to develop more potent, stable, and longer-lasting imaging probes for SPECT/PET imaging.

### 3.4. Theranostic Systems with Ultrasound Imaging

**Feature.** Ultrasound (US) is one of the most commonly used methods in diagnosis and disease therapy. Deep tissue penetration efficiency, safety, and noninvasive character are key aspects that mark the success of US in the medical field. \(^{165,166}\) US has emerged as a potent candidate in the delivery of diverse therapeutic agents (Figure 9). US aids in delivering the payload at the right time in the right place. \(^{167}\) The capacity of combined ultrasound imaging and synergetic chemoradiotherapy (CRT) was studied by Shang et al., who designed pH- and US-responsive perfluoropentane-encapsulated paclitaxel (PTX)-loaded carboxymethyl chitosan nanodroplets (NDs) by a homogenization/emulsion method. NDs presented enhanced proficiency in pH-dependent charge conversion, biocompatibility, and ultrasound contrast echogeneity. \(^{168}\) The results obtained through biochemical assays (CCK-8 assay; migration assay) and flow cytometry presented enhanced cell response in CRT for PTX-loaded NDs. Further, Zhiyi and co-workers designed DOX-loaded carboxymethyl-hexanoyl chitosan (CHC) NDs with a core of perfluoropentane (PFP) using an oil in water (O/W) emulsion method. \(^{169}\) An in vitro model was established to further evaluate the ultrasound imaging application of CHC-PFP-DOX NDs under different parameters. The antitumor effect of US combined with CHC-PFP-DOX NDs on ovarian cancer cells was also investigated. Ultrasound behaves as an external stimulus to enhance the drug releasing behavior as well as the cancer killing efficacy of the system. Though the designed system offered significant results at the in vitro level, the real-time functioning and biodistribution of any designed system under consideration could be adequately analyzed only after in vivo studies. In line with this, Baghbani et al. developed ultrasonic responsive alginate-stabilized perfluorohexane NDs with a size of around 100 nm for breast cancer therapy. DOX was loaded in the synthesized system and was evaluated for antitumor activity at in vitro and in vivo levels. Under the action of ultrasound triggering of drug release, the enhanced imaging capacity of the designed nanodroplets was confirmed. \(^{170}\) These studies hold great promise in delivering ultrasound-mediated cancer-targeting imaging along with delivery for cancer therapeutics.

Ultrasound-targeted delivery of nanobubbles (NBs) has also been credited as a promising approach for noninvasive drug delivery mechanism. Upon reduction of the size of US contrast agents, the intensity of the ultrasound echogenic signals decreases, which in turn reduces the stability of the bubbles. Consequently, designing NBs of size less than 200 nm with good imaging efficiencies and enhanced stability for long-term imaging in vivo has been the requirement to address the necessities of a designed system being marked as an efficient system for theranostic applications. To address this challenge, Zhou et al. designed a core–shell structure of approximately 120 nm in size with PFP as the core and chitosan as the shell of the NBs. DOX was loaded inside the NBs, and the system was studied for its drug delivery capacity. A clinical ultrasound imaging system was used to assess the capability of chitosan-based NBs for ultrasound triggered drug release and image enhancement. The anticancer effect of the designed chitosan-based NBs was evaluated following ultrasound-targeted nano/microbubble destruction (UTN/MD). \(^{171}\) Similar study was carried out by Yu and co-workers who designed PFP-filled chitosan poly(acrylic acid) (PPP-CS-PAA) NBs with a size of around 100 nm via a direct core-template-free strategy. The prepared PPP-CS-PAA NBs were reported to exhibit imaging capabilities in nude mouse tumors for 7 days, post-administration. \(^{172}\) These studies indicated the importance of...
Natural polymer-based hydrogels have also been used for ultrasound-triggered drug release. Huebsch et al. fabricated an alginate-based cross-linked hydrogel having the capacity to present US-triggered drug release along with self-healing properties. These hydrogels were prepared by cross-linking alginate cross with Ca²⁺. The study revealed negligible damage to the structure of hydrogels upon exposure to US but enhanced the drug release profile. The findings may provide vital insights in the area of US-responsive hydrogels. Working on a similar strategy, Husseini and his research group targeted the overexpressed hyaluronic acid (HA) receptor on the surface of breast cancer. They successfully synthesized PEGylated liposomes encapsulating the anticancer drug calcein and conjugated it to HA. Upon expose to low-frequency ultrasound, significant enhancement of calcein uptake was observed for breast cancer cells compared to the nonexposed cells. The studies emphasize the importance of ultrasound as an external stimulus with its application in instant switch-on and -off release of therapeutic molecule loaded in a carrier.

To achieve an effective theranostic platform for cancer treatment, multifunctionality in research should be implemented. The ultrasound-triggered drug release could be combined with growth factors or healing properties of the base material used. This will not only aid in the treatment and imaging process but also supplement the fast recovery and growth of healthy cells. Widespread experimental efforts should be made in the direction of designing ultrasound-triggered natural polymers like dextran, heparin, and so forth, which are under less consideration. This will help in widening the horizon of natural polymer-based theranostic platforms and could also be helpful in further understanding the interaction of these natural polymers at cellular and in vivo levels.

To further improve the treatment efficacy and diagnostic ability of theranostic agents, one has to be very cautious to check the incompatibilities between the medications that are to be administered and the imaging contrast agents of choice. There have been reports and clinical instances where water-soluble contrast media have shown incompatibility with a range of pharmacological agents including some vasodilators, antihistamines, and even antibiotics. Further, Zagoria et al. reported potential chemical incompatibility of low-osmolality contrast agents (hexabrix) with vasodilators (papaverine, tolazoline) used in angiography. It was observed that a mixture of hexabrix and papaverine produced a white precipitate, whereas hexabrix and tolazoline demonstrated temporary immiscibility. In the field of radiology, contrast agents and medications are frequently infused with indwelling intravenous lines. Incongruity between the contrast media and therapeutic molecules could result in precipitation which may have severe consequences like obstruction of the intravenous line, inactivation of the medication, and embolism. Choice of contrast agent and drug is very important when designing theranostic systems, as incompatibility among them may lead to severe consequences including discomfort for the patient and fatality.

Further, a key challenge in designing polysaccharide-based theranostics systems is the adverse effects that are associated with polysaccharide functionalization. In addition, formulating a controllable and reproducible process with minimal batch to batch variation also restricts the commercialization of polysaccharide-based theranostics systems. The choice of polysaccharide also plays an important role in formulating an effective theranostics system. Pore size, molecular weight, cross-link density, and mechanical attributes are some key parameters that could decide the fate of the designed system at both pre- and post-administration level. For example, MRI contrast of Gd-based contrast agent can be enhanced with the help of conjugation with various polymers (e.g., polysaccharides), as it helps in increasing the molecular weight of the system, which in turn affects the tumbling rate. Hence, in order to formulate an effective theranostic system, compatibility among the constituents along with the choice of application and targeted ailment has to be selected very wisely.

4. TOXICITY ASSESSMENT

Combination of therapeutic and imaging modalities in one probe, being a crucial feature of theranostic agents, may lead to contradicting expectations when applied in vivo. While a therapeutic agent aims at treatment of a disease with minimal impact to the healthy organs, an imaging agent is designed to visualize the pathology and be rapidly excreted from the body without any effects. Hence, the toxicity considerations must include both aspects and be approached carefully. As already mentioned, one of the strategies in designing theranostic agents is construction of nanomaterials. Therefore, in this section the potential toxicity assessment of polysaccharides along with each imaging modality will be reviewed first, followed by the discussion on general nanotoxicity.

4.1. Toxicity of Polysaccharides. In general, polysaccharides are nontoxic in nature, and many polysaccharides have been approved by the FDA for biomedical usage. However, there are studies which have reported the toxic effects of polysaccharides. Typically, chemical modifications and functionalization of polysaccharides have been associated with toxicity profiles. It is very interesting to note that the formulation strategies associated with polysaccharide-related probes alter the cellular uptake dynamics and affects their intrinsic safety profile. Studies conducted by Schipper et al. showed the toxic effects of chitosan of different molecular weight and degree of deacetylation (DD) on CaCo-2 cells, HT29-H, and in situ rat jejunum. Through this work, it was reported that higher DD in the case of high-molecular-weight chitosan imparts more toxic effects. Further, trimethyl chitosan (quaternized chitosan) has been reported with very low cytotoxicity (IC₅₀ > 10 mg/mL) for degrees of quaternization below 55%. However, Kean et al. reported the toxic effect of trimethyl chitosan with high degree of quaternization. This toxic effect was also reported in the case of higher-molecular-weight derivatives (100 kDa) of trimethyl chitosan. The derivatization of chitosan needs further examination in order to comprehend the safety profile linked with it for their widespread applicability. In another study, Flexner et al. reported slight toxicity associated with dextran sulfate when administered continuously in subjects exposed to symptomatic HIV. Profound but reversible thrombocytopenia was reported in subjects receiving drug for more than 3 days and extensive but reversible alopecia in a few subjects. Moreover, there have been few studies in which the anaphylactoid reaction of dextran has been reported in rats. Further, Seo et al. reported the genetic toxicity (chromosomal damage) incurred by dextran-coated SPION in HepG2 cells by formation of intracellular ROS. The study did not link dextran directly to the observed toxic effects, but...
the nontoxic nature of dextran in this study needs further investigation. In another study, Sokolsky et al. reported the toxicity of oxidized dextran on AW 264.7 cell line with an IC_{50} of 3 μmol/mL aldehydes.\textsuperscript{187} Although dextran is commercially used for many biomedical applications, analysis of the toxicity profile of their modified versions needs to be undertaken, for their utility at commercial levels. In order to investigate the toxicity profile of carboxymethyl cellulose (CMC), Baran et al. introduced CMC in the yolk sac of the zebrafish embryo.\textsuperscript{188} CMC showed negligible toxicity but was associated with increased lipid accumulation in a dose-dependent manner. Recently, in a study conducted by Fan et al., adverse effects were reported in rats upon administration of high doses of sodium CMC (2000 mg/kg), while trivial reactions were reported upon administration of mild doses (320 mg/kg).\textsuperscript{189}

Overall, polysaccharides are an integral part in designing healthcare tools which play an important role in many vital biomedical applications. Although not many toxicity issues have been linked with polysaccharides, new chemically modified derivatives of naturally occurring polysaccharides have been reported with certain adverse effects, if not severe. A detailed assessment of the safety profile of these derivatives will not only help to understand the in-depth cellular responses linked with their administration but also create a platform for their successful commercialization.

### 4.2. Toxicity of MRI Contrast Agents.

The contrast agents used in clinics to enhance MR images are typically small paramagnetic complexes that have been considered safe when used at the recommended doses of 0.1–0.3 mmol of metal ion kg\textsuperscript{-1}. Currently, the main concerns are related to the use of Gd\textsuperscript{3+}, as this lanthanide (Ln) ion, like all members of the series, is extremely toxic when released in its free form. The structures of the ligands complexing Gd\textsuperscript{3+} can be classified as macrocyclic or linear, in which the metal ion is incorporated either in a preorganized cage or in an open-chain molecule, respectively. The charge of the complexes can be neutral, anionic, or cationic. Thereby, macrocyclic and ionic complexes are considered more stable based on their kinetic and thermodynamic stability constants. High kinetic stability indicates dissociation rate of Gd\textsuperscript{3+} ion from the complex being significantly slower than the elimination rate of the entire contrast agent from the body, while high thermodynamic stability refers to the high energy required to release the free Gd\textsuperscript{3+}. The presence of competing ions (Zn\textsuperscript{2+}, Ca\textsuperscript{2+}, Mg\textsuperscript{2+}, etc.) in the bloodstream can additionally challenge the overall stability of the administered contrast agent by induction of the transmetalation process. The toxicity mechanism in this case is based on the exchange of Gd\textsuperscript{3+} with the endogenous ions in bones and skin.\textsuperscript{190} Furthermore, Gd\textsuperscript{3+} can act as a substituent of Ca\textsuperscript{2+} and block voltage-gated channels and/or interfere with the function of metabolic enzymes.\textsuperscript{191} Patients with normally functioning kidneys are able to eliminate >95% of the contrast agent within 24 h post-injection, while patients with renal dysfunction retain the complexes for a longer time during which dissociation of toxic Gd\textsuperscript{3+} can take place. The first indication of possible adverse effects by such patients was reported in 2006, when the use of Gd was associated with nephrogenic systemic fibrosis (NSF).\textsuperscript{192} Ten years later, deposition of Gd in the brain was documented for the patients that underwent repeated MRI examinations with a linear Gd\textsuperscript{3+}-complex Omniscan (Gd-DTPA-BMA),\textsuperscript{193} which was found to be 4-fold higher than for the cyclic contrast agent ProHance (Gd-HPDO3A).\textsuperscript{194} The explanation can be found in the literature reporting transformation of Gd-DTPA and Gd-DTPA-BMA upon entrapment by fibroblasts and macrophages and the subsequent enzymatic reaction leading to N-oxidation of the acetic pendant-arm and release of free Gd\textsuperscript{3+}.\textsuperscript{195}

In the search for alternative Gd-free contrast agents, much attention has been devoted to manganese (Mn), which is another paramagnetic metal with properties suitable for a sufficient positive contrast enhancement in MRI. In contrast with lanthanides, Mn is a systemic element that is part of the human diet and acts as a cofactor for metabolic enzymes and receptors. Despite demonstration of virtually no toxic effects in mice upon exposure to MnCl\textsubscript{2} for 3 weeks,\textsuperscript{196} the complexation of Mn\textsuperscript{2+} by strong chelators is still required for the design of safe contrast agents. The main reason for this is the neurotoxicity of Mn caused by deposition of free ions in the brain known as “manganism”, which is a neurodegenerative disorder resembling Parkinson’s. Currently, one of the best candidates for the chelation of Mn\textsuperscript{2+} is a hexadentate ligand N-picolyl-N,N′,N′-trans-1,2-cyclohexanediiminetreacetate (Py-C3A) that provides stable binding while maintaining high relaxivity. The dissociation of free Mn\textsuperscript{2+} from this complex in the presence of an excess of Zn\textsuperscript{2+} was reported to be 20 times lower than that of Mn-DTPA.\textsuperscript{197} Finally, Mn-nanoparticles become increasingly attractive due to literature data reporting good safety perspectives. However, the variety of Mn oxidation states (from −3 to +7) possibly coexisting during construction and especially application of nanoparticles should be considered, as some oxidation forms can enter redox reactions in vivo more easily than the others.\textsuperscript{198}

The lack of long-term tolerance data on the Gd-free MRI contrast agents, which are currently under intensive scrutiny, clearly represents a challenge, and effective technologies for introducing these agents into theranostic systems are still to be developed. However, the extensive knowledge gained with conventional contrast media will not only facilitate this process but also help to clarify whether the use of the alternatives is justified. There are reports that suggest that Gd could stay in the body for months to years after being introduced during an MRI scan, leading to gadolinium retention (accumulation in liver, kidney, bone, and brain).\textsuperscript{199,200} In order to understand cellular response to Gd and the pattern of removal, studies could be conducted using microfluidic-based 3D on chip models. The real-time information of these innovative devices could help in understanding many underlying mechanisms and further aid in developing new contrast-based strategies with acceptable safety concerns.

### 4.3. Toxicity of CT Contrast Agents.

Iodinated small-molecular contrast agents are applied routinely in clinics to enhance contrast in CT scans. The initially proposed sodium iodine was abandoned shortly after due to its systemic toxicity.\textsuperscript{201} The current CT contrast agents are typically mono- or dimeric derivatives of the benzene ring, where positions 2, 4, and 6 are substituted with iodine atoms, while other positions are functionalized with either ionic or nonionic groups. The binding of iodine to the benzene ring is stable, and the side chains make the molecules soluble in water; thus from this point of view, these contrast agents do not raise any toxicity concerns. However, the osmolarities and viscosities greater than those of the plasma or cerebrospinal fluid are known to cause mild adverse effects (e.g., itching and cutaneous reactions) as well as life-threatening emergencies (e.g., allergies or anaphylactic reactions).\textsuperscript{202} Contrast-induced
Less toxicity was reported for the nanoparticulate formulations extensively in the literature.209 On the other hand, the tracers considerations for such hybrid systems mainly concern for diagnosis where the high sensitivity of PET/SPECT is evolution of radionuclide imaging shows a clear preference concentrations required for sufficient contrast compared to classic iodine-based CT agents. Moreover, low signal-to-noise ratio due to either unspecific distribution of the tracer or the large size of the patient can in some cases be circumvented by the increase of the image acquisition time without exposure to a higher dose.212

Enclosure of radioisotopes into essential biomolecules without changing their properties, thus sustaining metabolic processes, is a common way to perform radionuclide imaging. Illustrative examples are 18FDG (18F t1/2 = 110 min) that is a gold standard used in PET for identification of abnormal glucose metabolism and 11C-methionine (11C t1/2 = 20 min) applied for the PET imaging of various cancers. Importantly, the administered doses per patient in these cases correlate as 1000 times lower than the corresponding concentrations of stable analogues that are considered toxic.213

Even though the small amounts of radiopharmaceuticals can provide activities sufficient for acquisition of images, a stable chelation is required in the case of metallic tracers to ensure their safe clinical application. For example, complexation of a common PET radioisotope 68Ga3+ by suitable small-molecular ligands (DOTA/NOTA) can prevent its binding to transferrin in vivo as the result of mimicking Fe3+.214 For some cations with a more complicated coordination core, such as a positron emitter 89/Zr4+ (t1/2 = 78.4h), the classic coordination yields a complex whose stability is not sufficient to endure the long exposure to the in vivo environment. The small atomic radius of Zr in combination with the variable coordination number (4–9) requires polyanionic hard donors for a stable complex formation. One of the accepted routes for a stable 89/Zr-complexation is utilization of the desferrioxamine moiety, which can additionally be applied in combination with various nanocarriers, e.g., dextran nanoparticles of 13 nm, that were demonstrated to be nontoxic in mice.215 The same strategy is carried out for conjugation of 86/Zr with monoclonal antibodies for PET imaging preceding radioimmunotherapy with 89/Y. As excretion of these peptide-based probes goes through the kidneys, retention of radioisotopes in the proximal tubules can potentially induce nephrotoxicity. A way around this problem was found in coadministration of negatively charged amino acids that competitively inhibit the binding of radioligands and reduce the radiation exposure of the kidneys.216

In conclusion, PET/SPECT radiopharmaceuticals administered in microdoses are not considered harmful as such. However, in theranostic formulations, longer retention/circulation times as well as possible repetition scans for response monitoring might cause adverse effects. Therefore, along with careful dose optimization, aspects such as pharmacokinetics, stability in the presence of enzymes, and metabolic pathways should be taken into account.

4.4. Toxicity of PET/SPECT Imaging Agents. The evolution of radionuclide imaging shows a clear preference for diagnosis where the high sensitivity of PET/SPECT is combined with the high anatomic resolution of CT. The safety considerations for such hybrid systems mainly concern exposure of the patients to the harmful X-ray radiation originating from the CT-modality, which is reviewed extensively in the literature.209 On the other hand, the tracers applied for both PET and SPECT imaging are less of a problem in terms of radiotoxicity, since they are generally short-lived radioisotopes that are excreted from the body by the renal system within 24 to 48 h after their intravenous administration. In this context, it is important to realize that the picomolar amounts of tracers administered for radionuclide imaging omit any chemotoxicity concerns, even if the elements involved are chemically toxic by nature. On the other hand, envisioning radionuclides for therapeutic purposes requires careful estimations of the radiation amount absorbed by the organs with the minimal off-target damage and the doses administered to the patients.210

Generally, the radiation dose to which a patient is exposed during PET and SPECT with conventional radiotracers ranges from 4 to 8 and 10 to 30 mSv, respectively. Advances in 3D imaging as well as extended-field-of-view and time-of-flight modalities typical for the new generation of PET-CT scanners allow for reduced doses of applied radiopharmaceuticals.211

In conclusion, PET/SPECT radiopharmaceuticals administered in microdoses are not considered harmful as such. However, in theranostic formulations, longer retention/circulation times as well as possible repetition scans for response monitoring might cause adverse effects. Therefore, along with careful dose optimization, aspects such as pharmacokinetics, stability in the presence of enzymes, and metabolic pathways should be taken into account.

4.5. Nanotoxicity. Initially, nanotherapeutics were considered in the clinic due to their ability to improve the effects of their small-molecular counterparts by increasing the solubility of drugs and reducing the required therapeutic dose through more effective accumulation in diseased organs. This approach introduced concerns on nanotoxicity, which is assessed routinely by in vitro experiments evaluating the cytotoxicity. However, aspects such as biodistribution, accumulation, metabolism, and excretion of nanoparticles play an important role in their clinical acceptance.

Among general toxicity issues reported for various nanoparticles, the most important ones are related to their size, shape, and surface activity that can be displayed at molecular, cellular, and tissue levels. Examples of such effects are induction of mesothelioma caused by carbon nanotubes due
to their elongated shape, size dependency of gold nanoparticles that are found to be toxic at a diameter of 1.4 nm compared to the nontoxic analogues of 15 nm diameter, and generation of reactive oxygen species (ROS) by iron oxide nanoparticles. An exception is microbubbles for ultrasound imaging that do not cause any toxicity concerns except for some rare and self-resolving allergic reactions.

Further, the surface of nanoparticles is prone to interaction with biomolecules present in biological fluids, which may not only alter the properties of the probe but most importantly also induce unfolding of proteins such as albumin, cytochrome, and ribonuclease, which subsequently compromises their function. Such effects have been reported for intravenously injected iron oxide nanoparticles that were shown to change the structure of transferrin by causing an undesired release of iron and as a result affecting the in vivo iron transport. Grafting of polymers to the surface of nanoparticles is a common way to bypass such undesired events and to prolong the blood circulation times of the nanoprobes to serve the theranostic purposes, but at the same time, it poses concerns related to hepatocellular toxicity. The main problem in this case remains the possibility for a long-term dissociation of metal ions and possible toxicity of the coating molecules. Biological and biocompatible macromolecules such as polysaccharides, PEG, and poly(lactic acid) have been demonstrated to be superior in this respect due to their nontoxicity and tolerance to mammalian tissues, provided sufficient coverage is applied. However, attention should be paid to the methods used for conjugation of the biomolecules to the surface of nanoparticles or cross-linking of the biopolymers to construct theranostic systems. For example, application of an efficient linker glutaraldehyde was shown to limit cell viability. Therefore, the preference should be given to biocompatible linkers, such as carbodiimide and succinic, malic, tartaric, and citric acids. Additionally, the surface charges originating from the coating molecules determine the nanotoxicity. Hoskins et al. compared PEGylation of SPIONs with poly(ethyleneimine) (PEI) coating and demonstrated cytotoxicity of PEI-nanoparticles due to higher positive charges, and hence greater formation of ROS and lipid peroxidation. The importance of an appropriate coating is furthermore clear from the examples of nanoparticles composed of biocompatible metals, such as gold. While cationic Au nanoparticles were demonstrated to induce oxidative DNA damage, the lysine-coated analogues were found to be nontoxic at concentrations up to 100 M.

Commonly, nanoparticles tend to exhibit less toxicity compared to their ionic equivalents; it was demonstrated that Au nanoparticles are ten times less toxic than Au ions that showed cytotoxicity at the concentrations of 25 mM. This phenomenon is based on the reduced chemical activity at the surface of nanoparticles, which additionally explains why smaller nanoparticles often display elevated cytotoxicity. However, degradation of nanoparticles and release of constituent ions can lead to subacute and long-term toxicity, such as genotoxicity or carcinogenesis. Given that the application of nanoparticles relies on the increased blood circulation, specific organ accumulation, and eventual elimination, this prolonged interplay can be expected to produce undesired effects after months or even years. Unfortunately, despite the wealth of in vitro and in vivo experimental data on the acute toxicity of nanoparticles, most long-term evaluations are limited to 13–14 weeks.

Exploiting the advantages of nanosystems in the design of theranostics, the immense variety of these materials as well as administration routes, frequency, and dose should be taken into account when it comes to toxicity evaluations. While the physicochemical characteristics are the first parameters determining the developments in the initial phase, a deep understanding of the toxicity mechanisms that are intrinsically different for nanoparticles compared to small molecular drugs/contrast agents may lead to fair predictions for the in vivo behavior of final formulations. This approach requires specialized toxicity assays for each phase of the development process, which will facilitate the acceptance of the designed theranostics in clinics. Finally, the growing variety of smart in vitro, in silico, and in vivo models closer to human pathologies will provide valuable information about the long-term effects of the new theranostic probes and facilitate their translation to the clinic.

5. CONCLUSIONS AND FUTURE PERSPECTIVES

In summary, polysaccharide-based multimodal theranostic systems exhibit significant benefits compared to the system designed for either therapeutics delivery or imaging. Here, the use of polysaccharides in combination with contrast agents provides the opportunity for loading different therapeutics (such as drug and gene) inside the natural polymer matrix to achieve imaging-guided therapy. In recent years, with the significant advancements in imaging instrumentation and development of new contrast agents, the area of theranostics has seen significant progress. However, there are still some limitations which need to be addressed at the laboratory level to achieve the successful use of developed theranostics at the clinical level.

Biocompatibility of theranostic systems is a prime requirement to ensure its widespread use. In cases where synthetic polymers are used to design theranostics, their degradation rate and the toxicity caused by the degraded products are major concerns which should be investigated along with finding an alternative solution. In this regard, polysaccharides present themselves as potential candidates owing to their inherent biocompatibility. The post-modification of polysaccharides in a controlled manner to achieve different chemical functionalities and their combination with natural materials from the human body itself could pave new pathways in the area of theranostics.

Another point of prime importance while designing a theranostic system is the target specificity. Research performed at the laboratory scale to fabricate a new theranostic system or to modify an existing theranostic system requires focusing the attention on developing strategies to make them target site-specific. In this regard, in vivo distribution of theranostic system should be investigated in detail. In this way, both contrast agent and drug could be delivered precisely to the diseased cells without harming the healthy cells.

Addressing the long- and short-term toxicity issues of contrast agents is also a vital area which needs attention. Working at the minimal required dose of contrast agent could be one such strategy that can offer a solution to the toxicity issue. With advancement in the field of microfluidics, real-time information on the cellular response along with investigation on the contrast property of the imaging media could be recorded. As the data obtained by microfluidic chips imitates the 3D microenvironment of targeted tissues, this will give a dedicated assessment of the minimal amount to be used. Another strategy that could be used to minimize the toxicity of
contrast media is the use of biomolecules and green chemistry-based synthesis. This will reduce the use of harmful chemicals for fabricating contrast agents and will aid in reducing the toxic effects of contrast media.

Further, thorough research investigation is required in terms of the doses of theranostics having contrast agents and drugs along with the gap between the doses. This will be ultimately influenced by the amount of contrast agent and drug that are loaded in the developed theranostic system. This area requires significant research with immediate attention as optimization of the contrast agent and drug amount in theranostics is very crucial for accomplishing simultaneous and efficient individual actions. For example, the use of iodinated contrast agents requires larger amounts to compensate for their faster excretion time. This higher amount may help in achieving images with better contrast, but it becomes problematic in terms of potential toxicity when CT scans at regular intervals are required for a patient to monitor the treatment progress. To address this, research has been performed where iodinated molecules have been attached to polymers or NPs. However, these systems require significant efforts to improve their efficiency by maximizing their performance and minimizing their toxicity.

In short, development of theranostic systems is an interdisciplinary area requiring expertise from chemistry, material science and engineering, nanotechnology, and medicine. Hence, several experts from different fields are now joining together to develop novel theranostic systems, with maximum clinical efficiency and minimum side effects, which will help in further improving human health in the near future.

■ AUTHOR INFORMATION

Corresponding Author
Garima Agrawal — School of Basic Sciences, Indian Institute of Technology, Mandi, Himachal Pradesh 175075, India; orcid.org/0000-0002-3391-2378; Email: garima@iitmandi.ac.in

Authors
Aastha Gupta — School of Basic Sciences, Indian Institute of Technology, Mandi, Himachal Pradesh 175075, India
Ankur Sood — School of Basic Sciences, Indian Institute of Technology, Mandi, Himachal Pradesh 175075, India
Erwin Fuhrer — School of Computing and Electrical Engineering, Indian Institute of Technology, Mandi, Himachal Pradesh 175075, India
Kristina Djanashvili — Department of Biotechnology, Delft University of Technology, 2629 HZ Delft, The Netherlands; orcid.org/0000-0003-1511-015X

Complete contact information is available at: https://pubs.acs.org/10.1021/acsbiomaterials.1c01631

Author Contributions
A.G. and A.S. are co-first authors. E.F. and K.D. contributed equally.

Notes
The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Support from Department of Science & Technology, GOI (DST/INSPIRE/04/2015/003220) and IIT Mandi (Seed grant: IITM/SG/GA/72) is highly acknowledged.

■ REFERENCES


(62) Yang, Y.; Jing, L.; Li, X.; Lin, L.; Yue, X.; Dai, Z. Hyaluronic Acid Conjugated Magnetic Prussian Blue@Quantum Dot Nanoparticles for Cancer Theranostics. Theranostics 2017, 7 (2), 466–481.


---

**Recommended by ACS**

**Nanotheranostic Pluronic-Like Polymeric Micelles: Shedding Light into the Dark Shadows of Tumors**

Cátia Domingues, Ana Figueiras, *et al.*

OCTOBER 21, 2019

MOLECULAR PHARMACEUTICS

**Size Preferences Uptake of Glycosilica Nanoparticles to MDA-MB-231 Cell**


SEPTEMBER 09, 2020

LANGMUIR

**Semiconducting Polymer Nanomaterials as Near-Infrared Photoactivatable Protherapeutics for Cancer**

Jingchao Li and Kanyi Pu

FEBRUARY 06, 2020

ACCOUNTS OF CHEMICAL RESEARCH

**Efficient Anticancer Drug Delivery for Pancreatic Cancer Treatment Utilizing Supramolecular Polyethylene-Glycosylated Bromelain**

Taishi Higashi, Hidetoshi Arima, *et al.*

APRIL 01, 2020

ACS APPLIED BIO MATERIALS

Get More Suggestions >